194 related articles for article (PubMed ID: 17373897)
1. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
Johnson BF; Clay TM; Hobeika AC; Lyerly HK; Morse MA
Expert Opin Biol Ther; 2007 Apr; 7(4):449-60. PubMed ID: 17373897
[TBL] [Abstract][Full Text] [Related]
2. Promising early results for immunotherapy-antiangiogenesis combination.
Garber K
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421345
[No Abstract] [Full Text] [Related]
3. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
4. Vascular biology support for the use of bevacizumab in colorectal cancer.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jun; 13(6):703-5. PubMed ID: 15174956
[TBL] [Abstract][Full Text] [Related]
5. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.
Wada J; Suzuki H; Fuchino R; Yamasaki A; Nagai S; Yanai K; Koga K; Nakamura M; Tanaka M; Morisaki T; Katano M
Anticancer Res; 2009 Mar; 29(3):881-8. PubMed ID: 19414323
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor inhibitors in colon cancer.
Díaz-Rubio E
Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
[TBL] [Abstract][Full Text] [Related]
7. A cancer treatment based on synergy between anti-angiogenic and immune cell therapies.
Soto-Ortiz L; Finley SD
J Theor Biol; 2016 Apr; 394():197-211. PubMed ID: 26826488
[TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
9. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
Kong DH; Kim MR; Jang JH; Na HJ; Lee S
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
[TBL] [Abstract][Full Text] [Related]
10. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of cancer in 2012.
Kirkwood JM; Butterfield LH; Tarhini AA; Zarour H; Kalinski P; Ferrone S
CA Cancer J Clin; 2012; 62(5):309-35. PubMed ID: 22576456
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
13. Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Huang Y; Goel S; Duda DG; Fukumura D; Jain RK
Cancer Res; 2013 May; 73(10):2943-8. PubMed ID: 23440426
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies: bevacizumab--has it reached its final resting place?
Kerr DJ; Young AM
Nat Rev Clin Oncol; 2011 Mar; 8(4):195-6. PubMed ID: 21386819
[No Abstract] [Full Text] [Related]
15. [Treatment with antiangiogenic drugs].
Saijo N
Nihon Rinsho; 2010 Jun; 68(6):1007-13. PubMed ID: 20535948
[TBL] [Abstract][Full Text] [Related]
16. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Ferrara N; Hillan KJ; Gerber HP; Novotny W
Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
[No Abstract] [Full Text] [Related]
17. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression.
Johnson B; Osada T; Clay T; Lyerly H; Morse M
Curr Mol Med; 2009 Aug; 9(6):702-7. PubMed ID: 19689297
[TBL] [Abstract][Full Text] [Related]
18. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
19. [Antiangiogenic therapy for gastrointestinal tumors].
Lakatos G; Tulassay Z
Orv Hetil; 2008 Dec; 149(49):2317-24. PubMed ID: 19042183
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
